Actinogen Medical Ltd has released a press release.
FDA Approval to Commence Alzheimers Disease Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Significant Advance in Development of Alzheimers Drug
- FDA Feedback on Xanamem Alzheimers Trail
- R&D Tax Rebate
- New Patents Allowed for B-HSD1 Inhibitor
- Further results in bio-ethanol test program
Later from Actinogen Medical
- Appendix 4C - quarterly
- Xanamem Research Published in Prestigious Medical Journal
- UK Regulatory Approval for Alzheimers Clinical Trial-XanADu
- Actinogen Medical Financial Results
- TGA Regulatory Approval for Alzheimers Phase II Trial
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical